



Media Contact:

Kara Maxwell

847.739.3249

kmaxwell@bionichepharmausa.com

Bioniche Pharma Launches Enlon[®] and Enlon-Plus[®] Injection

Lake Forest, IL, May 14, 2009 - Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced the launch of Enlon[®] (edrophonium chloride injection, USP) and Enlon-Plus[®] (edrophonium chloride, USP and atropine sulfate, USP) Injection.

“The acquisition and launch of Enlon[®] represent Bioniche Pharma’s continued growth and a commitment to bringing this important therapy back to market and into the hands of health care professionals,” said Steve Thornton, CEO Bioniche Pharma.

Bioniche Pharma purchased the rights and certain assets related to the Enlon[®] product line from Baxter Corporation, which discontinued Enlon[®] in February 2008. According to IMS data, 2007 sales of Enlon[®] and Enlon-Plus[®] totaled \$2,727,000 and 307,000 units.

Bioniche Pharma will supply Enlon[®] in 10 mg/mL, 15 mL vials and Enlon-Plus[®] in 15 mL vials, in addition to the currently available 5 mL ampul of Enlon-Plus[®].

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopedics, rheumatology, urology and dermatology. The company’s growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products. Bioniche Pharma was acquired in February 2006 by RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois. More information about Bioniche Pharma can be found at www.bionichepharma.com.

###